Introduction
Breast cancer is the most common cancer and a leading cause cancer-related death in females [1] . Although improvements in understanding the underlying mechanisms of breast cancer and developing new therapeutic approaches have been recently achieved, more than 400,000 women die from breast cancer every year [2] . Wnt/β-catenin signaling has been shown to play an important role in the development and promotion of into the nucleus of breast cancer cells. Additionally, in ER-positive breast cancers, NOP14 increase the level of ERα via NRIP1, implied that NOP14 can suppress breast cancer by inhibiting the Wnt/ β-catenin pathways possibly by up-regulating NRIP1 [25] . These findings provide new hope of developing targeted therapies against NOP14 and NRIP1 for breast cancer.
BKCa channel
The large conductance of calcium and voltage activated potassium (BKCa) channels function as oncogenes in breast cancers [26] . Through gene amplification, alternative splicing, and increased protein half-life, BKCa channels are overexpressed in many types of cancers [27] [28] [29] [30] . In glioma cells, BKCa channels are somewhat more sensitive to calcium and voltage than other BK channels, and thus generate K+ currents in environments where their normal counterparts are silent [27] . Higher grade tumors, characterized by enhanced growth and invasiveness, express more BK channels than lower grade tumors [27] . BKCa channels generate vast amounts of outward K+ currents and therefore are powerful modulators of the transmembrane potential of a cell. The investigators observed that BKCa channels also function as oncogenes in β-catenin-positive breast cancer; they direct their oncogenic input towards sustaining the tumorigenic ability of cancer cells; inhibitors of BKCa channels may modulate in vitro tumorigenesis via transmembrane depolarization. It is therefore plausible for BKCa channels to be considered putative targets for anticancer therapies.
Emilin2
Emilin2 is an extracellular matrix (ECM) protein that exerts antagonistic effects in the tumor microenvironment. By activating the extrinsic apoptotic pathway, Emilin2 affects tumor cell viability [31, 32] . It is directly up-regulated by miR-320 and is part of a fibroblast secretome profile that correlates with clinical outcome in breast cancer patients [33, 34] . The molecular regulations governed by Emilin2 in breast cancer have been investigated. Marastoni et al. identified Emilin2 as a novel molecular partner of Wnt1 and demonstrated that this interaction led to a significant inhibition of the Wnt signaling pathway. Emilin2 can halt the expression of β-catenin target genes through decreasing LRP6 phosphorylation and β-catenin activation. They also observed that Emilin2 binds to Wnt1 and impairs Wnt signaling activation in vitro and in vivo experiment. Therefore, Emilin2 can slow cell cycle
Wnt/Calcium Pathway
Calcium signaling activity is sufficient to activate calcium sensitive enzymes, including protein kinase C (PKC), calcium dependent kinase II (CamKII) or calcineurin (CaCN) [13] . PLC cleaves phosphatidylinositol-4, 5-bisphosphate (PIP2) into inositol-1, 4, 5-trisphosphate (IP3) and diacylglycerol (DAG) [14] . IP3 binds to IP3 receptors, which release Ca2+ from subcellular stores such as the endoplasmic reticulum (ER) [15] . Activated calcineurin dephosphorylates the transcription factor and nuclear factor of activated T-cells (NFAT), allowing NFAT to translocate into the nucleus where it activates NFATresponsive genes [16] .
Based on a better understanding of all the diverse functions of Wnt and their molecular mechanisms in recent years, additional targets associated with Wnt signals pathway have been discovered. In this review, we make a summary on these new targets. Investigating the protein and gene, which is associated with Wnt signals pathway, will provide a theoretical basis for targeted treatment of breast cancer.
NOP14
NOP14 is a stress-responsive gene that is required for 18S rRNA maturation and 40S ribosome production, interacting with PAXIP1, which plays a critical role in maintaining genome stability, condensation of chromatin and progression through mitosis, containing tandem breast cancer carboxyl-terminal domains and regulating multiple aspects of the cellular response to DNA damage, such as cell survival and differentiation [17] [18] [19] [20] [21] [22] . Recent studies have suggested that NOP14 may be related to cancer development. In prostate cancer cells, NOP14, a target gene of the polycomb repressive complex, plays a critical role in neoplastic progression [23, 24] . Moreover, high levels of NOP14 mRNA and protein were observed in the fibrocystic breast cell line MCF10A; whereas the levels of NOP14 mRNA and protein were low in the four breast cancer cell lines. Strikingly, NOP14 levels contrast with the malignancy of human breast cancer, which is high in atypical ductal hyperplasia (ADH) and primary cancer but low in the advanced breast cancer tissues. Importantly, the investigators discovered that NOP14 could assemble β-catenin on the membranes of breast cancer cells and prevent its nucleus translocation and the following activation. NOP14 increased APC and β-catenin levels, as well as GSK-3β phosphorylation level in breast cancer cells, and inhibited the entry of β-catenin have concluded that WISP2 plays a dual role in the progression of breast and pancreatic cancer, acting as an oncogenic promoter at early stages of tumor development and subsequently, at later stages, as a suppressor of the invasive phenotype [48] [49] [50] . Corresponding studies have suggested that less aggressive breast cancer cell lines highly express WISP2, compared to low levels of WISP2 that non-transformed cells express [50] . WISP2 knock-down in less aggressive breast cancer cell lines is accompanied by estrogen-independent cell growth, and isassociated with the loss of estrogen receptor alpha (ERa) expression and increased expression of key components of TGF-β signaling pathway thereby promoting EMT [51] , which is similar to WISP1. Furthermore, the researchers suggest that WISP2 can block expression of miR-10b [52] , a non-coding RNA known as a role in invasion and metastasis [53] . altogether, these findings suggest that the loss of WISP2 is linked to breast cancer progression [54] , accompanied by both EMT induction and increased stemness. These data suggest that WISP2 is a novel target for the development of more efficient therapies toward breast cancer.
MicroRNA
MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression at a post-transcriptional level and monitor several biological processes [55] . Several human miRNAs have been shown to regulate the metastasis of breast cancer cells [56] .
MicroRNA-100 (miR-100) is a member of the miR-100 family of miRNAs and is widely expressed in vertebrates [57] . However, the role of miR-100 in cancers seems to be confounded, since it can act either as an oncogene or as a tumor suppressor in different tumor types [58, 59] . In recent years, the investigators discovered that miR-100 functions to suppress breast cancer cell movement and invasion by inhibiting proliferation and survival-promoting oncogene insulin-like growth factor (IGF) 2. In addition, miR-100 can inhibit breast tumorigenesis [60] and target HOXA1 [61] . HoxA1 is transcriptionally regulated by retinoic acid (RA) and encodes a transcription factor which has been shown to play important roles in cell differentiation and embryogenesis. Jiang et al observed that the overexpression of MiR-100 could inhibit the migration and invasion of breast cancer cells by transfecting miR-100 mimic in aggressive breast cancer cell lines and transfecting miR-100 inhibitor in non-metastatic cell lines. This mechanism involves MiR-100 directly inhibiting the expression of FZD-8 and inactivating the progression and reduce cell motility, impairing breast cancer cell growth and development [35] . These findings reveal a further mechanism that Emilin2 suppresses tumor growth, providing evidence of the key role of the microenvironment during tumor development and reinforcing the therapeutic potential of this molecule.
WISP
WISP1 is located on chromosome 8q24.1-q24.3, contains 5 exons and 4 introns, and is a secreted matrix cellular protein found in the extracellular matrix (ECM) [36] . Human WISP1 was first identified in a human mammary epithelial cell line with Wnt-1 expression and shown to be a Wnt-1-induced gene in 1998 [37] . As well as other ECM proteins, WISP1 affects cell responses, including differentiation, proliferation, migration, and survival [36] . In stromal cells in the proximity of tumors WISP1 overexpression leads to an increase in tumor growth through paracrine signaling [38, 39] . Additionally, transfecting WISP1 into melanoma cells inhibited tumor cell growth [40] . Overexpression of WISP1 down-regulated the invasion and migration of lung cancer cells, leading to reduced metastatic potential [41] . However, the investigators found that WISP1 expression were increased in tumor cells in vivo, including colon, lung, liver, and breast cancer [37, [42] [43] [44] . Chiang et al. discovered that WISP1 functions as an oncogene for human breast cancer. Ectopic expression of WISP1 in breast cancer cells promotes cell growth and metastasis, represses p21 and p27 expression, and stimulates EMT. WISP1, NDRG1, a tumor suppressor gene for breast cancer, is repressed by WISP1 through DNA sequences within the NDRG1 promoter [45] . Thus, WISP1 is a human breast cancer oncogene and is a potential therapeutic target. The epithelial-mesenchymal transition (EMT) has been associated with the acquisition of motility, invasiveness, and self-renewal traits. During both normal development and tumor pathogenesis, this change in cell phenotype is induced by contextual signals that epithelial cells receive from their microenvironment. p21 is a potent cyclindependent kinase inhibitor (CKI). The p21 (CIP1/WAF1) protein binds to and inhibits the activity of cyclin-CDK2, -CDK1, and -CDK4/6 complexes, and thus functions as a regulator of cell cycle progression at G1 and S phase. p27 is a cell-cycle regulatory protein that Interacts with cyclin-CDK2 and -CDK4, inhibiting cell cycle progression at G1.
WISP2, a 29-kDa protein, belonging to the cysteinerich 61/connective tissue growth factor/ nephroblastoma overexpressed (CCN) family [46] , was believed to act as a potential proliferation module [47] . The investigators act as adaptors in several receptor-mediated signaling pathways [71] . Reports have indicated that TRAF4 can enhance transcription of β-catenin and may protect it from p53-mediated degradation [72] . A review indicated that TRAF4 had a negligible effect on Wnt in early Xenopus embryonic tissue [8] . Studies have shown that the TRAF4 is highly expressed in breast cancer tissue. In a similar manner as β-catenin it can promote cell migration and metastasis in breast cancer [73, 74] . Wang et al. discovered that TRAF4 can bind to β-catenin and enhance expression of β-catenin; in addition, they also found that TRAF4 mediated the translocation of β-catenin from the cytoplasm to the nucleus, thereby facilitating activation of the Wnt signaling pathway in breast cancer.
Wntless (Wls)/Evi/Sprinter/ GPR177
Wntless (Wls)/Evi/Sprinter/GPR177 is a seven-pass transmembrane protein, which is highly conserved and localized to compartments of the secretory pathway among vertebrates including the Golgi apparatus, endosomes, and plasma membrane [75, 76] . As a Wnt cargo receptor, Wls shuttles palmitoylated Wnts from the endoplasmic reticulum to the plasma membrane, and is also required for exocytosis of Wnt proteins from the Wnt-producing cells [77] [78] [79] . Knockdown of Wls leads to an accumulation of Wnts in the producing cells [80] , resulting in early embryonic patterning defects [81] . Moreover, Wls deficiency impairs mammary development which interferes with mammary stem cells, causing deficiencies in cell proliferation and differentiation [82] . We found that Wls has been overexpressed in several kinds of cancers, such as glioblastoma, colorectal cancer, B cell precursor acute lymphoblastic leukemia (BCP ALL), ovarian cancer, and gastric cancer in the past few years [83] [84] [85] . Additionally, Wls could promote glioma cell proliferation and invasion through regulating Wnt secret ion and upregulation of interleukins and other pro-oncogenic factors [82] . Some studies demonstrate that Wls inhibits melanoma cell proliferation through the β-catenin signaling pathway [86] . The strong Wls expression observed in cancer suggests a potential role for Wls in breast tumorigenesis. Downregulation of Wls could reduce colony formation and tumor cell growth through inhibiting the secretion of Wnt and its downstream signaling. Our results indicate that Wls might be able to promote proliferation of breast cancer cells and may provide a new therapeutic target for breast cancer.
Wnt/β-catenin pathway in breast cancer cells. MiR-100 functions as a tumor suppressor in breast cancer cells and the manipulation of miR-100 provides a promising therapeutic strategy for breast cancer treatment.
MiR-340 has been studied as a putative tumor suppressor in several cancers including neurofibromatosis type 1, neuroblastoma, ovarian tumor, and gastric cancer [62] [63] [64] . The investigators have shown that MiR-340 suppresses cell migration, invasion, and metastasis in these cancers due to its over-expression [65] . Moreover, in vitro, the investigators confirmed that over-expression of MiR-340 regulates motility of cancer cells and decreases cell mobility and invasion. The restoration of miR-340 expression presents a novel therapeutic strategy for preventing breast cancer progression and metastasis if we undertake more comprehensive investigations and trials.
MiRNA-301a has attracted much attention due to its important role in various biological and pathological processes, including development, differentiation, inflammation, apoptosis and cancer [66] [67] [68] . Ma et al. have shown that MiR-301a is involved with breast cancer development and metastasis by directly targeting PTEN to activate the Wnt/β-catenin pathway, revealing the oncogenic role of miR-301a in breast cancer. Inhibition of miR-301 presents a promising therapeutic strategy for breast cancer treatment
NRBP1
NRBP1 is a ubiquitously expressed adapter protein [69] . Recently it has been discovered that it can suppress tumors [70] in cytoplasm and nucleus, where it has been detected. Additionally, it has been demonstrated to predominantly localize in the cytoplasm. In vitro studies have suggested that NRBP1 shuttles between the nucleus and cytoplasm, functioning to regulate protein localization and undertake transcription factor activity. NRBP1 has also been implicated with cancer development. Not only were NRBP1 levels reduced in breast cancer tumor tissues, but NRBP1 expression level and breast cancer clinic pathological features were correlated in patients. Importantly, the Wnt signaling pathway could regulate NRBP1-induced cancer cell proliferation. Based on this information, NRBP1 could be a potential therapeutic target for suppressing breast cancer metastasis.
TRAF4
Tumor necrosis factor receptor-associated factor 4 (TRAF4) is a member of the TRAF family, whose members 
Conclusion
The Wnt signaling pathway plays an integral role in malignant cell growth, proliferation, motility, and survival of tumors, and is widely observed in breast cancer. As previously summarized, an increasing number of new targets have been identified that inhibit Wnt signaling. Much work remains to be done in to apply this new information to clinical treatments and to develop novel Wnt signaling inhibitors. XAV-939 can selectively inhibit the transcription mediated by Wnt/β-catenin through inhibiting tankyrase1/2. ICG-001 suppress the transcription mediated by Wnt/β-catenin/TCF and selectively interacting promoter binding protein. Overall, the diversity and rationale behind the use of Wnt/β-catenin targets support the Wnt signaling inhibitors as promising therapeutics. Although most drugs are still at a very early developmental stage, the importance of this pathway makes breast cancer a strong candidate to benefit from these new therapies. It is important not to oversell the promise of Wnt signaling-based therapies, but continued research will, we believe, help to solve some of these vexing issues. The result is certain to be exciting, and will lead to new insights that translate to better therapies for breast cancer.
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